GTR Home > Tests > SmartGenomics Complete Solid Tumor Profile with Microsatellite Instability Analysis

Overview

Test order codeHelp: SMGNGSEST_MSI

Test name

Help

SmartGenomics Complete Solid Tumor Profile with Microsatellite Instability Analysis (SMGNGSEST_MSI)

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Drug Response, Predictive, Prognostic

Condition

Help

65 conditions tested. Click Indication tab for more information.

How to order

Help

SMGNGSEST_MSI

Specimen source

Paraffin block

Methodology

Help
Molecular Genetics
IMicrosatellite instability testing (MSI)
PCR
TTargeted variant analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)

Summary of what is tested

160 genes and variants, 5 analytes. Click Methodology tab for more information.

Genes

Analytes

  • BAT-25
  • BAT-26
  • MONO-27
  • NR-21
  • NR-24

Clinical utility

Help

Not provided

Clinical validity

Help

Not provided

Suggested reading

Practice guidelines

  • ACMG, 2016
    Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
  • ACMG, 2015
    ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing.
  • ACMG/NSGC, 2015
    A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
  • ASCO, 2014
    American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
  • ACMG, 2013
    ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
  • ASCO, 2010
    American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
  • ASCO, 2009
    American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment
  • ACS, 2007
    American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
  • NSGC, 2004
    Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors.
  • ASCO, 2003
    American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
  • ASHG/ACMG, 1995
    Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents
  • ACMG SF v3.0, 2021

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center